Mark Cuban on healthcare insurers and PBMs: ‘They have become too big to care’

Mark Cuban, Founder of Mark Cuban Cost Plus Drug Company
Mark Cuban, Founder of Mark Cuban Cost Plus Drug Company | X

Mark Cuban, founder of the Mark Cuban Cost Plus Drug Company, said that genuine healthcare price relief necessitates dismantling vertically integrated insurers and controlling pharmacy benefit manager (PBM) fees, facility fees, and 340B margin abuses.

"Who exactly is going to cut their prices ? Independent physicians can barely pay their bills," said Cuban. "Hospitals are going to get rid of facility fees or walk away from keeping 340b margins and passing that to the patient ? No. Big PBMs are going to stop charging fees ? No. Break up the big insurance companies first."

According to the Federal Trade Commission's (FTC) interim staff report on prescription-drug middlemen, the PBM industry is highly concentrated and increasingly linked to major insurers and affiliated pharmacies. The report indicated that these connections enable PBMs to engage in practices that "profit at the expense of patients and independent pharmacists," including steering patients and charging opaque fees. This highlights growing policy scrutiny of PBMs' market power.

State lawmakers are also challenging hospital "facility fees," which can inflate bills when outpatient sites are billed as part of a hospital. By September 2025, 20 states had enacted laws to limit or make these fees more transparent, reflecting concerns that hospital consolidation allows extra charges not tied to actual patient care. Advocates argue this trend ensures savings are passed on to patients.

A study published in the New England Journal of Medicine found that hospitals participating in the 340B drug program experienced financial gains; however, those benefits did not result in increased care or reduced death rates for low-income patients. The research observed more hospital-physician partnerships and hospital-based drug administration but noted that vulnerable patients did not clearly see improvements—raising concerns about whether the program's savings reach those most in need.

The network behind 340B profits has expanded significantly. According to USC Schaeffer, the number of "child sites" associated with hospitals rose from approximately 1,339 in 2010 to over 36,000 today, or roughly 13 per 340B hospital. The program now collaborates with over 33,000 contract pharmacies as of 2024, covering more than half of all U.S. pharmacies. This extensive network raises oversight questions and helps explain why charity-care results often lag despite larger discounts.

Cuban is an American businessman, investor, and television personality known for founding the Mark Cuban Cost Plus Drug Company in 2022 to enhance transparency and affordability in prescription drug pricing. The company sells generic medications at cost plus a 15% margin and pharmacy fee, aiming to bypass traditional PBMs and reduce patient expenses.